CRISPR THERAPEUTICS AG (CRSP) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 13.39M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $13.39M | (m) | (m) |
| 2026-03-31 | (m) | $4.10M | (m) | (m) |
| 2025-12-31 | (m) | $3.51M | (m) | (m) |
| 2025-09-30 | (m) | $38.34M | (m) | (m) |
| 2025-06-30 | (m) | $38.05M | (m) | (m) |
| 2025-03-31 | (m) | $37.67M | (m) | (m) |
| 2024-12-31 | (m) | $37.31M | (m) | (m) |
| 2024-09-30 | (m) | $202.83M | (m) | (m) |
| 2024-06-30 | (m) | $202.23M | (m) | (m) |
| 2024-03-31 | (m) | $271.71M | (m) | (m) |
| 2023-12-31 | (m) | $371.21M | (m) | (m) |
| 2023-09-30 | (m) | $170.01M | (m) | (m) |
| 2023-06-30 | (m) | $170.10M | (m) | (m) |
| 2023-03-31 | (m) | $100.26M | (m) | (m) |
| 2022-12-31 | (m) | $1.20M | (m) | (m) |
| 2022-09-30 | (m) | $14.09M | (m) | (m) |
| 2022-06-30 | (m) | $14.82M | (m) | (m) |
| 2022-03-31 | (m) | $915.36M | (m) | (m) |
| 2021-12-31 | (m) | $914.96M | (m) | (m) |
| 2021-09-30 | (m) | $902.43M | (m) | (m) |
| 2021-06-30 | (m) | $901.76M | (m) | (m) |
| 2021-03-31 | (m) | $1.10M | (m) | (m) |
| 2020-12-31 | (m) | $719.00K | (m) | (m) |
| 2020-09-30 | (m) | $77.36M | (m) | (m) |
| 2020-06-30 | (m) | $289.14M | (m) | (m) |
| 2020-03-31 | (m) | $289.42M | (m) | (m) |
| 2019-12-31 | (m) | $289.59M | (m) | (m) |
| 2019-09-30 | (m) | $212.69M | (m) | (m) |
| 2019-06-30 | (m) | $1.32M | (m) | (m) |
| 2019-03-31 | (m) | $2.09M | (m) | (m) |
| 2018-12-31 | (m) | $3.12M | (m) | (m) |
| 2018-09-30 | (m) | $35.33M | (m) | (m) |
| 2018-06-30 | (m) | $37.16M | (m) | (m) |
| 2018-03-31 | (m) | $39.65M | (m) | (m) |
| 2017-12-31 | (m) | $41.00M | (m) | (m) |
| 2017-09-30 | (m) | $11.02M | (m) | (m) |
| 2017-06-30 | (m) | $10.18M | (m) | (m) |
| 2017-03-31 | (m) | $7.39M | (m) | (m) |
| 2016-12-31 | (m) | $5.16M | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $247.00K | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |